Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
Shares of Theravance Biopharma TBPH plunged 26% after the company announced the failure of the late-stage CYPRESS study evaluating ampreloxetine, an investigational, once-daily norepinephrine reuptake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results